Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
Chin Med J (Engl). 2009 Oct 20;122(20):2405-11.
MicroRNAs (miRNAs) are small noncoding regulatory RNAs whose aberrant expression may be observed in many malignancies. However, few data are yet available on human primary medulloblastomas. This work aimed to identify that whether miRNAs would be aberrantly expressed in tumor tissues compared with non-tumorous cerebellum tissues from same patients, and to explore a possible role during carcinogenesis.
A high throughput microRNA microarray was performed in human primary medulloblastoma specimens to investigate differentially expressed miRNAs, and some miRNAs were validated using real-time quantitative RT-PCR method. In addition, the predicted target genes for the most significantly down- or up-regulated miRNAs were analyzed by using a newly modified ensemble algorithm.
Nine miRNA species were differentially expressed in medulloblastoma specimens versus normal non-tumorous cerebellum tissues. Of these, 4 were over expressed and 5 were under expressed. The changes ranged from 0.02-fold to 6.61-fold. These findings were confirmed using real-time quantitative RT-PCR for most significant deregulated miRNAs (miR-17, miR-100, miR-106b, and miR-218) which are novel and have not been previously published. Interestingly, most of the predicted target genes for these miRNAs were involved in medulloblastoma carcinogenesis.
MiRNAs are differentially expressed between human medulloblastoma and non-tumorous cerebellum tissue. MiRNAs may play a role in the tumorigenesis of medulloblastoma and maybe serve as potential targets for novel therapeutic strategies in future.
微小 RNA(miRNAs)是小的非编码调节 RNA,其异常表达可能在许多恶性肿瘤中观察到。然而,目前关于人类原发性髓母细胞瘤的数据很少。本研究旨在确定与来自同一患者的非肿瘤小脑组织相比,肿瘤组织中是否存在 miRNA 的异常表达,并探索其在癌变过程中的可能作用。
对人原发性髓母细胞瘤标本进行高通量 microRNA 微阵列分析,以研究差异表达的 miRNA,并使用实时定量 RT-PCR 方法验证部分 miRNA。此外,使用新修改的集成算法分析最显著下调或上调 miRNA 的预测靶基因。
在髓母细胞瘤标本与正常非肿瘤小脑组织之间,有 9 种 miRNA 表达水平存在差异。其中,有 4 种 miRNA 过表达,5 种 miRNA 低表达。这些变化的范围从 0.02 倍到 6.61 倍。使用实时定量 RT-PCR 对最显著失调的 miRNA(miR-17、miR-100、miR-106b 和 miR-218)进行验证,这些 miRNA 是新发现的,以前没有发表过。有趣的是,这些 miRNA 的大多数预测靶基因都涉及髓母细胞瘤的发生。
miRNA 在人髓母细胞瘤和非肿瘤小脑组织之间存在差异表达。miRNA 可能在髓母细胞瘤的发生中起作用,并可能成为未来新的治疗策略的潜在靶点。